ANIK Quote, Financials, Valuation and Earnings

GB Sciences, Inc. has a net margin of -11.41% compared to Anika Therapeutics, Inc.'s net margin of --. Anika Therapeutics, Inc.'s return on equity of -9.18% beat GB Sciences, Inc.'s return on equity of --.

Anika Therapeutics, Inc. has a consensus price target of $16.00, signalling upside risk potential of 25.1%. On the other hand GB Sciences, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Anika Therapeutics, Inc. has higher upside potential than GB Sciences, Inc., analysts believe Anika Therapeutics, Inc. is more attractive than GB Sciences, Inc..

Anika Therapeutics, Inc. has a beta of 0.433, which suggesting that the stock is 56.666% less volatile than S&P 500. In comparison GB Sciences, Inc. has a beta of 11.330, suggesting its more volatile than the S&P 500 by 1032.978%.

Anika Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GB Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Anika Therapeutics, Inc. pays -- of its earnings as a dividend. GB Sciences, Inc. pays out -- of its earnings as a dividend.

Anika Therapeutics, Inc. quarterly revenues are $27.8M, which are larger than GB Sciences, Inc. quarterly revenues of --. Anika Therapeutics, Inc.'s net income of -$3.2M is lower than GB Sciences, Inc.'s net income of -$190.5K. Notably, Anika Therapeutics, Inc.'s price-to-earnings ratio is -- while GB Sciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Anika Therapeutics, Inc. is 1.63x versus 1.26x for GB Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Iovance Biotherapeutics, Inc. has a net margin of -11.41% compared to Anika Therapeutics, Inc.'s net margin of -82.92%. Anika Therapeutics, Inc.'s return on equity of -9.18% beat Iovance Biotherapeutics, Inc.'s return on equity of -54.64%.

Anika Therapeutics, Inc. has a consensus price target of $16.00, signalling upside risk potential of 25.1%. On the other hand Iovance Biotherapeutics, Inc. has an analysts' consensus of $8.80 which suggests that it could grow by 132.19%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than Anika Therapeutics, Inc., analysts believe Iovance Biotherapeutics, Inc. is more attractive than Anika Therapeutics, Inc..

Anika Therapeutics, Inc. has a beta of 0.433, which suggesting that the stock is 56.666% less volatile than S&P 500. In comparison Iovance Biotherapeutics, Inc. has a beta of 0.765, suggesting its less volatile than the S&P 500 by 23.531%.

Anika Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Iovance Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Anika Therapeutics, Inc. pays -- of its earnings as a dividend. Iovance Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Anika Therapeutics, Inc. quarterly revenues are $27.8M, which are smaller than Iovance Biotherapeutics, Inc. quarterly revenues of $86.7M. Anika Therapeutics, Inc.'s net income of -$3.2M is higher than Iovance Biotherapeutics, Inc.'s net income of -$71.9M. Notably, Anika Therapeutics, Inc.'s price-to-earnings ratio is -- while Iovance Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Anika Therapeutics, Inc. is 1.63x versus 5.14x for Iovance Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Protokinetix, Inc. has a net margin of -11.41% compared to Anika Therapeutics, Inc.'s net margin of --. Anika Therapeutics, Inc.'s return on equity of -9.18% beat Protokinetix, Inc.'s return on equity of -111.59%.

Anika Therapeutics, Inc. has a consensus price target of $16.00, signalling upside risk potential of 25.1%. On the other hand Protokinetix, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Anika Therapeutics, Inc. has higher upside potential than Protokinetix, Inc., analysts believe Anika Therapeutics, Inc. is more attractive than Protokinetix, Inc..

Anika Therapeutics, Inc. has a beta of 0.433, which suggesting that the stock is 56.666% less volatile than S&P 500. In comparison Protokinetix, Inc. has a beta of 0.614, suggesting its less volatile than the S&P 500 by 38.569%.

Anika Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protokinetix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Anika Therapeutics, Inc. pays -- of its earnings as a dividend. Protokinetix, Inc. pays out -- of its earnings as a dividend.

Anika Therapeutics, Inc. quarterly revenues are $27.8M, which are larger than Protokinetix, Inc. quarterly revenues of --. Anika Therapeutics, Inc.'s net income of -$3.2M is lower than Protokinetix, Inc.'s net income of -$84.9K. Notably, Anika Therapeutics, Inc.'s price-to-earnings ratio is -- while Protokinetix, Inc.'s PE ratio is 23.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Anika Therapeutics, Inc. is 1.63x versus -- for Protokinetix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of -11.41% compared to Anika Therapeutics, Inc.'s net margin of -316.61%. Anika Therapeutics, Inc.'s return on equity of -9.18% beat Plus Therapeutics, Inc.'s return on equity of --.

Anika Therapeutics, Inc. has a consensus price target of $16.00, signalling upside risk potential of 25.1%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1595.96%. Given that Plus Therapeutics, Inc. has higher upside potential than Anika Therapeutics, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Anika Therapeutics, Inc..

Anika Therapeutics, Inc. has a beta of 0.433, which suggesting that the stock is 56.666% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.

Anika Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Anika Therapeutics, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Anika Therapeutics, Inc. quarterly revenues are $27.8M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Anika Therapeutics, Inc.'s net income of -$3.2M is higher than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Anika Therapeutics, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Anika Therapeutics, Inc. is 1.63x versus 5.20x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.